NCT07063745 2026-04-07
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
Clinical Trials
9 trialsNCT06926868 2026-04-01
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07076121 2026-03-31
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07365319 2026-01-26
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Not yet recruiting
NCT07318883 2026-01-06
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT05254171 2024-11-06
ASPIRE
Panbela Therapeutics, Inc.
Phase 2/3 Recruiting
NCT04435652 2020-06-17
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed